Pharmaceuticals
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial
BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first pati...
2021-02-10 19:51
2292
New 3M™ Polisher™ ST reduces the number of biopharma manufacturing process steps
ST. PAUL, Minn., Feb. 9, 2021 /PRNewswire/ -- 3M Health Care launched 3M™ Polisher™ ST,* an advanced, single-use AEX solution designed to replace reusable AEX polishing column for biologic drug manufacturing. Polisher ST improves the biopharma manufacturing workflow by reducing the number of pro...
2021-02-10 00:07
6246
endpoint Clinical Announces the Appointment of Christine Hurley as its Senior Vice President, Client Services
SAN FRANCISCO, Feb. 9, 2021 /PRNewswire/ -- endpoint Clinical, an industry-leading global interactive response technology (IRT) company, has appointed Christine Hurley as its Senior Vice President, Client Services. Bringing over 20 years of experience in clinical operations and technology, Chri...
2021-02-09 22:00
5031
neoX Biotech closes US$30 million Series A round
BEIJING, Feb. 9, 2021 /PRNewswire/ -- neoX Biotech, a next-generation biotech company specializing in computational design for novel drug research and development, recently announced that it had raisedUS$30 million in Series A funding.The financing was co-led by Sky9 Capital and 5Y Capital (forme...
2021-02-09 21:28
3772
Regent Pacific's Strategic Partner Obtains Clinical Trial Approval for FORTACIN(TM)
HONG KONG, Feb. 9, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that Wanbang Biopharmaceutical...
2021-02-09 20:35
8444
Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China
TORONTO and SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance Pharma for commercialization in theGreater China region. Nuance is a biopharmaceutical company focused on licensing, developing and com...
2021-02-09 20:00
6095
Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China
SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Yingli Pharma announced today that it reached strategic collaboration with Hengrui Medicine (600276.SH), a partnership which will significantly accelerate the expansion of Yingli Pharma's oncology business inChina, the second largest pharmaceutical market in...
2021-02-09 08:30
2343
The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
* Greatly increase the company's current capacity to 90,000L and enable WuXi Biologics to initiate any project within four weeks * Offer flexible large-scale manufacturing services by implementing Scale-out strategy WUXI, China, Feb. 9, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.H...
2021-02-09 08:25
2962
Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma
SAN FRANCISCO and SUZHOU, China, Feb. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dis...
2021-02-09 08:00
9004
Inova Appoints Claude Basset as Chief Product Officer
LYON, France, Feb. 8, 2021 /PRNewswire/ -- Inova, the market-leading partnering platform for the pharmaceutical and biotech industry, today announced that Claude Basset has joined their leadership team as Chief Product Officer. Inova is a French Tech success story that, now in its 10th year, ha...
2021-02-08 16:00
1632
Orpha Labs AG Initiates Compassionate Use Program for ORL-101 in Leukocyte Adhesion Deficiency Type II (LAD-II)
First Patient to Receive ORL-101 in Israel This Week BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel ...
2021-02-08 15:00
3455
Sihuan Pharmaceutical (0460.HK) The sole agent of Letybo 100U China AI Listing Conference was successfully held
HONG KONG, Feb. 5, 2021 /PRNewswire/ -- Exclusively represented by Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460), Letybo®100U, a type A botuli...
2021-02-05 11:32
6552
Global survey presented at the Digital Liver Cancer Summit 2021 reveals heavy toll of COVID-19 first wave on liver cancer care
GENEVA, Feb. 5, 2021 /PRNewswire/ -- The delays of screening programmes, diagnostic imaging and biopsies, cuts in the numbers of physicians available to treat liver cancer patients, cancellations of surgery, and a drop in the number of patients entered on clinical trials, were just some of the is...
2021-02-05 07:00
2947
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb.4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Pha...
2021-02-04 20:30
2056
Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B
SINGAPORE, Feb. 4, 2021 /PRNewswire/ -- Gilead Sciences announced today at the 2021 Asian Pacific Association for the Study of the Liver Conference (APASL), findings from two sub-analyses that demonstrated the continued efficacy and improved safety of Vemlidy® (tenofovir alafenamide 25 mg, TAF) ...
2021-02-04 12:00
5093
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
Not intended for distribution in the USA, Canada or UK - TEPMETKO is approved for both treatment naïve and previously treated MET ex14 positive NSCLC patients - TEPMETKO demonstrated consistent and durable responses in both treatment naïve and previously treatedMETex14 patients in the VISION stud...
2021-02-04 02:57
1892
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-02-03 12:30
10150
Elekta's MOSAIQ and Versa HD earn top honors in 2021 Best in KLAS: Software and Services Report
ATLANTA, Feb. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that itsMOSAIQ® Oncology Information System (OIS) and Versa HD™ linear accelerator have been named "Best in KLAS" in the 2021 Best in KLAS: Software and Services Report. MOSAIQ was ranked first in the Oncology (Radiation) ca...
2021-02-03 00:30
3969
Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine
CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Feb. 2, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, announced today that the first healthy volunteer has been successfully dos...
2021-02-02 20:00
2214
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer
SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company recently released ...
2021-02-02 17:24
2346
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 290 media titles]
2025-12-16 08:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 287 media titles]
2025-12-16 14:26
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
